ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA (Nasdaq: ADMA) announced a 2026 capital return initiative targeting $200 million, including a $125 million accelerated share repurchase (ASR) with JPMorgan, and plans to complete the ASR within about five months.
The company will initially receive ~6.4 million shares (≈80% of expected ASR shares) based on a $15.57 close on Feb 27, 2026, and retains up to $500 million authorized repurchases.
Positive
- $125M ASR executed with JPMorgan
- Capital return target of $200M for 2026
- Initially received ~6.4M shares (~80% of ASR)
- Up to $500M total repurchase authorization
Negative
- Final ASR share count depends on VWAP and an agreed discount
- At settlement, company may need to deliver shares or pay cash
- Repurchases could limit near-term cash available for other investments
Details
News Market Reaction – ADMA
On Mar 2, the day this news came out, ADMA closed 6.49% above the previous close. That session’s volume was 2.1x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- 2026 capital return target
- $200 million
- Planned 2026 total share repurchase initiative
- ASR size
- $125 million
- Accelerated share repurchase with JPMorgan in 2026
- Initial ASR shares
- 6.4 million shares
- Approximate initial shares received under ASR
- Initial ASR proportion
- 80%
- Portion of total ASR shares delivered upfront
- Reference share price
- $15.57 per share
- Closing price on February 27, 2026 used for initial ASR sizing
- ASR duration
- five months
- Expected term to complete ASR
- Repurchase authorization
- $500 million
- Total capacity under existing share repurchase program
- Repurchases to date
- $160 million
- Cumulative repurchases since May 2025 including ASR
Historical Context
-
Record FY2025 results with strong revenue, ASCENIV growth, and higher long-term guidance.
-
Announcement of Q4 and FY2025 earnings release date and accompanying conference call.
-
Preliminary FY2025 revenue, cash position, raised 2026–2027 guidance, and SG‑001 plans.
-
Planned J.P. Morgan Healthcare Conference presentation and webcast details.
-
3Q 2025 revenue, profitability metrics, yield‑enhanced production, and raised guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
volume-weighted average price technical
rule 10b5-1 trading plans regulatory
sec rule 10b-18 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately
“We believe ADMA’s common stock represents the most compelling near-term capital deployment opportunity available to the Company,” said Adam Grossman, President and Chief Executive Officer of ADMA. “Given our sustained revenue growth, expanding margins and an anticipated acceleration in go-forward cash flow generation, we believe we are well positioned to continue investing in our strategic growth initiatives while returning significant capital to stockholders. We view our common stock as meaningfully undervalued relative to the strength and durability of our business and remain highly confident in our ability to drive substantial long-term per-share value.”
Under the terms of the ASR agreement, ADMA will pay JPMorgan an aggregate upfront amount of
The ASR agreement was executed pursuant to the Company’s existing share repurchase program, under which the Company has up to
Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “view,” “positioned,” “support,” “should,” “could,” “would,” “may,” “potential,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s long-term growth trajectory, capital deployment, cash flow forecast, strategic growth initiatives, value of our common stock, ability to deliver stockholder value, timing for completion of the ASR transaction, the number of shares to be purchased by JPMorgan under the ASR agreement, and additional purchases in 2026 under our share repurchase program. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.